Introduction

Pharma industry in India

The Indian Pharmaceutical Industry has witnessed the sharp growth
from the past few years. In the year 1990 the turnover is
approximately US $ 1 billion. The country now ranks 3rd in world by
volume of production and 14th by value, thereby accounting around
for 10% world’s production by volume and 1.5% by value.
India exported $11.7 billion worth of Pharmaceuticals in 2014. The
Pharma products are exported to various nations by India.
Pharmaceutical Industry accounts 6% of the total FDI of the country.
The increase in FDI flows has helped in the expansion, growth and
development of the industry.

Government’s Contribution.
 During the year the Indian Government established the
Department of Biotechnology under the Ministry of Science and
Technology. Since, there have been a number of dispensations
offered by both the Central government and various states to
encourage the growth of the industry.
 Indian Govt launched a program to provide tax incentives and
grants for biotech start-ups and helping the firms which are
seeking to expand.
 Indian Govt establishes the Biotechnology Parks society of India
to support ten biotech parks.
 The Department of Pharmaceuticals has prepared a “Pharma
Vision 2020” document. The objective of this document is for
making India as one of the leading destinations for end-to-end
drug discovery and innovation.
 The Government is also embarking on a major multi-billion
dollars initiative with 50% public funding through a PPP model
to improve India’s innovation capability.
  The government also plans to set up a Pharmacopeial
Commission to support Ayurveda, Yoga and Naturopathy,
Unani, Siddha and Homoeopathy (AYUSH) through guidelines
laid down in the review of the Eleventh Plan.

Future of Pharma Industry in India

 India acquired 14th rank in Global Pharma Industry during 2005
(6 US billion $). India is projected as 10th largest market in
Pharma industry.
 In India the cost of manufacturing pharma products are less and
effective comparing to other countries. India have strong
manufacturing base. Due to the technology development the
high skilled work force is available in India. The marketing and
distribution system is also on the higher side in India by
communication development. The diverse ecosystem also
strengthens the sector.
 India’s “Look East” policy aims at reducing trade dependencies
on the US and the EU.
 The Union Cabinet took a decisive step to establish three API
parks with common utilities, identifying and reducing the
dependencies on China for 53 APIs, introduced the Production
Linked Incentive (PLI) scheme to further reiterate India’s aim
to be self-reliant.
 Prediction and Early detection is a core pillar of the future of
health. We expect that over the next 20 years, we will be able to
detect some diseases—and prevent them from advancing—
possibly even before symptoms surface.
  Personalized or customized treatment. A customized treatment
as a single therapy, or mix of therapies, that is selected, tailored,
or developed to treat an individual.
 960+ Companies are developing potential cures, US$8.9B+
Investments in cell and gene therapies in 2019, 1000+ Ongoing
clinical trials.